Literature DB >> 9103485

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

H L Kaplan1, U E Busto, G J Baylon, S W Cheung, S V Otton, G Somer, E M Sellers.   

Abstract

Enzymatic conversion of hydrocodone to hydromorphone is catalyzed by cytochrome P450 2D6, which is inactive in about 7% of Caucasians [poor metabolizers (PMs)] and can be inhibited by quinidine pretreatment in the remainder [extensive metabolizers (EMs)]. If hydromorphone, having a substantially higher mu-receptor affinity than hydrocodone, contributes importantly to the physiological and subjective effects of oral hydrocodone, then PMs should be less responsive to the same doses, and quinidine pretreatment should cause EMs to temporarily respond as PMs. Seventeen EMs and 8 PMs who previously responded positively to hydromorphone s.c. received placebo and hydrocodone (10 mg, 15 mg and 22.5 mg p.o.) and were retested with their favorite dose after placebo or quinidine (100 mg) pretreatment; physiological and subjective measures were collected at base line and four times after drug administration, and urine was collected for 8 hr. EMs and PMs were equally responsive to oral hydrocodone, and quinidine had no consistent effect on their responses, even though quinidine abolished the pre-existing metabolic differences in hydromorphone production, as measured in urine. These data suggest only a small role of hydromorphone in eliciting abuse-related responses to oral hydrocodone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103485

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

Review 3.  Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Authors:  Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

Review 4.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.

Authors:  Murad R Melhem; Christopher M Rubino; Stephen J Farr; Cynthia Y Robinson
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

7.  CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Authors:  Mark R Hutchinson; Andrew Menelaou; David J R Foster; Janet K Coller; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

8.  The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Michelle R Lofwall; Joseph R Holtman
Journal:  Drug Alcohol Depend       Date:  2008-07-07       Impact factor: 4.492

Review 9.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2014-01-23       Impact factor: 6.875

10.  Pharmacogenomic considerations in opioid analgesia.

Authors:  Pascal H Vuilleumier; Ulrike M Stamer; Ruth Landau
Journal:  Pharmgenomics Pers Med       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.